Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers

Paediatric Drugs
Aiqun LiHaojing Rong

Abstract

Guanfacine extended-release (GXR) is an orally administered, non-stimulant treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and is primarily metabolized by the 3A4 isozyme of cytochrome P450 (CYP3A4). The results of clinical pharmacokinetic (PK) studies indicate that guanfacine is sensitive to drug-drug interactions (DDIs) perpetrated by strong inhibitors and inducers of CYP3A4. The aim was to provide guidance on the possible requirement for GXR dose adjustment in children and adolescents with ADHD by predicting DDIs following co-administration with moderate CYP3A4 inhibitors and inducers. A physiologically based PK model for GXR orally administered to healthy adults was developed based on physicochemical, in vitro and clinical PK data. The model was validated using clinical PK data for co-administration of GXR with ketoconazole (strong CYP3A4 inhibitor) or rifampicin (strong CYP3A4 inducer). Model predictions indicated that co-administration of GXR with the moderate CYP3A4 inhibitors erythromycin 500 mg three times a day or fluconazole 200 mg daily (q.d.) increased the guanfacine area under the plasma concentration-time curve (AUC) by 2.31-fold or 1.98-fold, respectively, compared wit...Continue Reading

References

Jan 1, 1980·British Journal of Clinical Pharmacology·J R Kiechel
May 20, 1999·Annual Review of Pharmacology and Toxicology·F P Guengerich
Jan 11, 2000·Clinical Pharmacokinetics·S N de WildtJ N van den Anker
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Stéphane MoulyPaul B Watkins
Sep 12, 2002·Clinical Pharmacokinetics·Jane Alcorn, Patrick J McNamara
Nov 14, 2003·Journal of Managed Care Pharmacy : JMCP·Karen M StocklAmy R Perwien
Aug 24, 2004·European Child & Adolescent Psychiatry·Eric TaylorAlessandro Zuddas
Oct 8, 2004·Clinical Pharmacology and Therapeutics·Jiansong YangAmin Rostami-Hodjegan
Feb 17, 2006·Annals of Clinical Microbiology and Antimicrobials·Jiezhong Chen, Kenneth Raymond
Jun 10, 2006·The Journal of Pharmacology and Experimental Therapeutics·Aleksandra Galetin, J Brian Houston
Jun 14, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·E M HowgateA Rostami-Hodjegan
Mar 21, 2007·Pharmaceutical Research·Trudy Rodgers, Malcolm Rowland
Nov 6, 2007·Current Drug Metabolism·Jiansong YangAmin Rostami-Hodjegan
Oct 18, 2011·Pediatrics·UNKNOWN Subcommittee on Attention-Deficit/Hyperactivity DisorderSusanna Visser
Mar 9, 2012·Clinical Pharmacology and Therapeutics·E D KharaschT Kim
Aug 25, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Liusheng HuangFrancesca T Aweeka
Nov 22, 2013·Nucleic Acids Research·UNKNOWN NCBI Resource Coordinators
Feb 13, 2014·Expert Opinion on Drug Metabolism & Toxicology·Italo PoggesiAchiel Van Peer
Dec 1, 2004·Drug Discovery Today. Technologies·Amin Rostami-Hodjegan, Geoff Tucker
Mar 1, 2015·Clinical Pharmacokinetics·William KnebelMarc R Gastonguay
Aug 25, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jennifer E SagerNina Isoherranen
Mar 31, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lisa M AlmondJane R Kenny

❮ Previous
Next ❯

Citations

Jun 9, 2019·European Journal of Drug Metabolism and Pharmacokinetics·Jing LiNa Gao
May 28, 2019·Clinical Pharmacokinetics·Gaëlle MaglioccoYoussef Daali
Nov 28, 2019·The Pharmacogenomics Journal·Giovanna Soldatelli BorsatoWilliam D Freeman
Jan 29, 2019·Journal of Thrombosis and Thrombolysis·Bruria Hirsh RaccahYosef Kalish
Nov 18, 2017·The Oncologist·Manuela Schmidinger, Romano Danesi
Mar 30, 2019·European Archives of Psychiatry and Clinical Neuroscience·Georgios SchoretsanitisMichael Paulzen
Jun 27, 2020·Hematological Oncology·Alessandra SerraoAntonio Chistolini
Dec 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Teruo MurakamiNicholas Bodor
Aug 11, 2019·Current Topics in Medicinal Chemistry·Yue ZhouKun Sun
Jul 22, 2020·Clinical Pharmacology and Therapeutics·Sara N SalernoUNKNOWN Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee

❮ Previous
Next ❯

Software Mentioned

Simcyp

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.